| Literature DB >> 31941128 |
Zhiyuan Fan1,2, Zhaoxin Geng1,3, Weihao Fang1,2, Xiaoqing Lv1, Yue Su1,2, Shicai Wang4, Hongda Chen1,2.
Abstract
Detecting biomarkers is an efficient method to diagnose and monitor patients' stages. For more accurate diagnoses, continuously detecting and monitoring multiple biomarkers are needed. To achieve point-of-care testing (POCT) of multiple biomarkers, a smartphone biosensor system with the multi-testing-unit (SBSM) based on localized surface plasmon resonance (LSPR) integrated multi-channel microfluidics was presented. The SBSM could simultaneously record nine sensor units to achieve the detection of multiple biomarkers. Additional 72 sensor units were fabricated for further verification. Well-designed modularized attachments consist of a light source, lenses, a grating, a case, and a smartphone shell. The attachments can be well assembled and attached to a smartphone. The sensitivity of the SBSM was 161.0 nm/RIU, and the limit of detection (LoD) reached 4.2 U/mL for CA125 and 0.87 U/mL for CA15-3 through several clinical serum specimens testing on the SBSM. The testing results indicated that the SBSM was a useful tool for detecting multi-biomarkers. Comparing with the enzyme-linked immunosorbent assays (ELISA) results, the results from the SBSM were correlated and reliable. Meanwhile, the SBSM was convenient to operate without much professional skill. Therefore, the SBSM could become useful equipment for point-of-care testing due to its small size, multi-testing unit, usability, and customizable design.Entities:
Keywords: localized surface plasmon resonance; microfluidics; multipoint biosensor; point-of-care; protein detection; smartphone
Year: 2020 PMID: 31941128 PMCID: PMC7014366 DOI: 10.3390/s20020446
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Figure 1Schematic of the chip integrated with the microfluidic channel and picture of AuNPs. (a) The SEM (scanning electron microscope) image of AuNPs on a silicon substrate. Insert Figure: side view of AuNPs on a silicon substrate. Scale bar: 300 nm; (b) The AFM (atomic force microscope) image of AuNPs; (c) Schematic of the microfluidic chip; (d) The real picture of the chip.
Figure 2Schematic of attachments of the SBSM (smartphone biosensor system with the multi-testing-unit). (a) The schematic of attachments; (b) The detail of the case; (c) The detail (top view) of the stage of micro-hole array and small-lens array; (d) The picture of attachments and the smartphone; (e) The working principle of the SBSM.
Figure 3Spectral calibration results. (a) Picture of lasers taken by the smartphone; (b) Relationship between intensity and position in the picture of lasers; (c) Relationship between wavelength and position; (d) The spectrum of 532 nm laser and the Gauss fitting curve.
Figure 4Results of refractive index measurement. (a) Picture taken by the smartphone on the SBSM. (b); The grayscale spectrum of the rainbow picture; (c) Normalized absorption spectrum with and without sucrose solutions; (d) Relationship between wavelength shift and refractive index measured by the smartphone and the spectrometer.
Figure 5Functionalization of AuNPs. (a) The reaction between AuNPs and 11-MUA; (b) Active carboxyl via EDC and NHS; (c) Bonding antibody; (d) Quench amine reaction by ethanolamine.
Figure 6Reference curve of CA125 and CA15-3. (a) Reference curve of CA125 ranges from 0–40 U/mL; (b) Reference curve of CA15-3 ranges from 0–40 U/mL.
Figure 7Results of interference testing when the LSPR chip was functionalized by (a) anti-MUC1 (for CA125); (b) anti-MUC16 (for CA15-3).
Figure 8Data comparing results measured by the SBSM and results provided by the hospital. (a) The concentration of CA125 measured by the SBSM and ELISA (enzyme-linked immunosorbent assays); (b)The concentration of CA15-3 measured by the SBSM and ELISA. Blue dash line: reference line where concentrations measured by the SBSM and ELISA were equal.
Figure 9Concentration of CA125 and CA15-3 in serum samples. (a) The concentration of CA125. Gray dash line at 35 U/mL, which is the reference concentration of CA125 in clinic; (b) The concentration of CA15-3. Gray dash line at 25 U/mL, which is the reference concentration of CA125 in clinic.